Aug 14, 2026, 1:55 PM ETConference Presentation, Panel

Aligning Investment and Opportunity in Health | Global Conference 2026

M&A activity has accelerated earlier than expected, with $140 billion spent acquiring public companies in the last six quarters.
Since April 1, 2025, $105 billion has been deployed specifically in public company M&A, representing a "recycling" of capital into the ecosystem.
Public company fundraising has rebounded significantly; average raises have increased from $100 million a year ago to $250–$400 million currently.
Approximately $20 billion of recycled capital has been redeployed into existing public companies in the first half of the current year.
New IPOs are returning to the market, predominantly featuring later-stage companies with higher probabilities of success compared to the pre-2021 cycle where success rates were under 10%.
Large pharmaceutical companies have undergone a decade of "corporate clarity," divesting consumer health (e.g., Tylenol, Band-Aid) and animal health businesses to become pure-play innovators.
To achieve a mere 4% annual growth rate over the next five years, top pharma firms require approximately $70 billion in risk-adjusted sales from new acquisitions.
The XBI (biotech index) has surged 65–70% since "Liberation Day" a year ago, outperforming the S&P 500's 35% gain, driven by growth sentiment.

The U.S. spends roughly $400 billion annually on novel medicines, representing 8% of total healthcare spending and $3 per American per month.
This spending drives approximately $300 billion in annual R&D investment, creating the primary incentive structure for global drug innovation.
Coverage decisions are increasingly driven by the operational burden on billing directors; high volumes of prior authorization requests for a specific drug signal market demand to insurers.
Insurance plans are more likely to cover a drug when billing directors prioritize their approval due to patient advocacy and the volume of rejections handled.
Pharmaceutical pricing and R&D focus are heavily influenced by Medicare negotiation rules introduced in the Inflation Reduction Act (IRA).
A "dead zone" has emerged for small molecules targeting non-orphan diseases of aging (e.g., Alzheimer's, heart failure) due to nine-year price controls post-launch.
The industry is shifting toward chronic therapies for earlier-stage indications (e.g., first-line oncology) to avoid depleting patent life in the "pocketed" years before generic competition.
Investors are avoiding areas with 9-year patent exposure; antibodies (13 years) and orphan drugs (exempt from negotiation) remain viable investment targets.

U.S. and European biopharma are increasingly licensing and developing Chinese-originated innovations, as Chinese companies lack the infrastructure for U.S./EU clinical trials and commercialization.
To facilitate deals, Chinese companies often transfer assets to offshore subsidiaries, as U.S. investors find domestic cap tables with significant Chinese ownership difficult to navigate.
U.S. Phase 1 biotech firms are increasingly moving to China to leverage faster clinical trial speeds and robust IP protection in specific therapeutic areas.
Running early-stage trials in China is cheaper and faster, but later-stage (Phase 2/3) trials must still be conducted in the U.S. and Europe to meet regulatory standards.
The U.S. relies on international patient enrollment (e.g., UK, Australia, Canada) for clinical trials; the UK study on dexamethasone (IL-6) is cited as a critical example of international contribution to U.S. drug efficacy.
There is concern regarding a potential "brain drain" of scientists moving to China, though experts note that market size and patient demographics, not just scientist location, drive where innovation occurs.
Future global drug revenue potential depends on China's economic growth; at 1% of GDP, China could reach a $400 billion annual novel medicine market in 40–50 years.
Policymakers are urged to avoid "Most Favored Nation" (MFN) policies that could isolate the U.S. from global contributions and inadvertently cede the market to China.

AI is not expected to revolutionize near-term drug discovery (predicting molecule efficacy) due to insufficient high-quality biological data to train models on human disease complexity.
The validation loop for AI claiming to increase drug success rates (e.g., from 10% to 20%) is statistically slow, requiring hundreds of clinical trials to prove significance.
Current AI applications are more impactful in operational efficiency: reducing clinical trial recruitment times, optimizing trial design, and lowering development costs by 20%.
AI is expected to have a more immediate and significant impact on healthcare delivery efficiency, specifically in streamlining prior authorization and reimbursement processes.
The market has not seen a successful "Tech-Enabled Drug Development" (TE-DD) company that remains a pure tech service provider; such entities inevitably become traditional biotechs to generate value.
Investors view "SaaS-style" drug development models as distinct from traditional biotech, often resulting in a disconnect between tech investors' return expectations and biological risk.
AI tools are being utilized to optimize operational tasks, such as shortening FDA approval submission times, rather than predicting biological success.

Investment is shifting away from non-orphan small molecules for aging diseases due to the price control risks associated with the Inflation Reduction Act.
There is growing capital allocation toward neuropsychiatric and CNS disorders (e.g., intractable depression, schizophrenia) despite the lack of clear surrogate endpoints.
The GLP-1 success has validated obesity as an investable area, overcoming previous skepticism stemming from the "fen-phen" era.
Significant innovation is occurring in inflammation and immunology, making previously hard-to-treat conditions highly manageable.
Organ failure (heart, lung, kidney, liver) is identified as an emerging "tsunami" opportunity, with early clinical trials now underway for xenotransplantation (e.g., pig organs).
Precision oncology strategies have collapsed in the small molecule space, with companies avoiding late-line (4th/5th line) indications to preserve patent life for earlier, more profitable indications.
Industry leaders emphasize the need for internal corporate advocacy (e.g., HR and employees urging insurers to cover critical drugs) to generate the market signals necessary for R&D investment.